中恒集团：控股子公司获得药品补充申请批准通知书

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Amikacin (0.5g), which is expected to enhance the product's market competitiveness and future market expansion [1] Group 1: Product Approval - The approval notification for Amikacin injection is a significant milestone for Laimei Pharmaceutical, as it allows the company to strengthen its position in the market [1] - Amikacin is indicated for treating infections caused by sensitive Gram-negative bacteria, including urinary tract infections, lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1] Group 2: Market Data - According to MoShang data, the sales revenue of Amikacin in Chinese hospitals is projected to be CNY 259 million, CNY 220 million, and CNY 40 million for the years 2023, 2024, and the first half of 2025, respectively [1] - As of the date of the announcement, Laimei Pharmaceutical has invested a total of CNY 6.3781 million in the research and development of Amikacin (unaudited data) [1] Group 3: Competitive Landscape - The approval is expected to improve the market competitiveness of Amikacin, which has been produced by 12 manufacturers that have passed the consistency evaluation [1]